Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 2,266 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $42.42, for a total value of $96,123.72. Following the completion of the transaction, the senior vice president now owns 52,977 shares in the company, valued at $2,247,284.34. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Acceleron Pharma Inc (NASDAQ:XLRN) traded down $1.46 during mid-day trading on Thursday, reaching $42.94. The company’s stock had a trading volume of 332,656 shares, compared to its average volume of 275,733. The company has a market capitalization of $1,929.73, a price-to-earnings ratio of -16.58 and a beta of 1.59. Acceleron Pharma Inc has a 52-week low of $23.07 and a 52-week high of $44.80.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.55) earnings per share. equities analysts forecast that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.

A number of brokerages have commented on XLRN. BidaskClub upgraded Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Royal Bank of Canada began coverage on Acceleron Pharma in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $44.00 price objective on the stock. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Wednesday, September 20th. Barclays increased their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, September 20th. Finally, HC Wainwright assumed coverage on Acceleron Pharma in a research report on Thursday, October 12th. They issued a “buy” rating and a $57.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $44.56.

A number of hedge funds have recently bought and sold shares of XLRN. Quantbot Technologies LP lifted its holdings in Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,352 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Acceleron Pharma by 969.9% during the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,288 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Acceleron Pharma during the third quarter worth about $225,000. PNC Financial Services Group Inc. lifted its holdings in Acceleron Pharma by 57.8% during the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in Acceleron Pharma during the third quarter worth about $266,000. Hedge funds and other institutional investors own 85.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/04/acceleron-pharma-inc-xlrn-svp-sells-96123-72-in-stock.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.